A Randomized, Open-label, Phase 3 Study to Evaluate 9MW2821 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Have Previously Received Taxane-based Chemotherapy With or Without Immunotherapy and an Antibody-drug Conjugate With a Topoisomerase Inhibitor Payload
Latest Information Update: 05 May 2026
At a glance
- Drugs Bulumtatug Furvedotin (Primary)
- Indications Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Mabwell (Shanghai) Bioscience
Most Recent Events
- 29 Apr 2026 New trial record